Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 162

1.

Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202.

Wanga V, Venuto C, Morse GD, Acosta EP, Daar ES, Haas DW, Li C, Shepherd BE.

Pharmacogenet Genomics. 2015 Sep;25(9):450-461.

PMID:
26148204
2.

Genital Cytomegalovirus Replication Predicts Syphilis Acquisition among HIV-1 Infected Men Who Have Sex with Men.

Gianella S, Smith DM, Daar ES, Dube MP, Lisco A, Vanpouille C, Margolis L, Haubrich RH, Morris SR.

PLoS One. 2015 Jun 10;10(6):e0130410. doi: 10.1371/journal.pone.0130410. eCollection 2015.

3.

Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s.

Longenecker CT, Kitch D, Sax PE, Daar ES, Tierney C, Gupta SK, McComsey GA; AIDS Clinical Trials Group Study A5224s Team.

J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):168-77. doi: 10.1097/QAI.0000000000000557.

PMID:
26009829
4.

Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols.

Moore CB, Verma A, Pendergrass S, Verma SS, Johnson DH, Daar ES, Gulick RM, Haubrich R, Robbins GK, Ritchie MD, Haas DW.

Open Forum Infect Dis. 2015 Jan 9;2(1):ofu113. doi: 10.1093/ofid/ofu113. eCollection 2015 Jan.

5.

A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens.

Broglio KR, Daar ES, Quintana M, Yuan Y, Kalsekar A, Spellberg B, Lewis RJ, Akker Dv, Detry MA, Le T, Berry SM.

J Comp Eff Res. 2015;4(2):101-14. doi: 10.2217/cer.14.69.

PMID:
25825840
6.

Cystatin C-based renal function changes after antiretroviral initiation: a substudy of a randomized trial.

Gupta SK, Kitch D, Tierney C, Daar ES, Sax PE, Melbourne K, Ha B, McComsey GA; AIDS Clinical Trials Group Study A5224s Team.

Open Forum Infect Dis. 2014 Apr 16;1(1):ofu003. doi: 10.1093/ofid/ofu003. eCollection 2014 Mar.

7.

A Remotely-Delivered CBT and Contingency Management Therapy for Substance Using People with HIV.

Moore BA, Rosen MI, Wang Y, Shen J, Ablondi K, Sullivan A, Guerrero M, Siqueiros L, Daar ES, Liu H.

AIDS Behav. 2015 Jun;19 Suppl 2:156-62. doi: 10.1007/s10461-014-0990-x.

PMID:
25645326
8.

Plasma and Cerebrospinal Fluid Biomarkers Predict Cerebral Injury in HIV-Infected Individuals on Stable Combination Antiretroviral Therapy.

Anderson AM, Harezlak J, Bharti A, Mi D, Taylor MJ, Daar ES, Schifitto G, Zhong J, Alger JR, Brown MS, Singer EJ, Campbell TB, McMahon DD, Buchthal S, Cohen R, Yiannoutsos C, Letendre SL, Navia BA; HIV Neuroimaging Consortium.

J Acquir Immune Defic Syndr. 2015 May 1;69(1):29-35. doi: 10.1097/QAI.0000000000000532.

PMID:
25622053
9.

Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.

Lehmann DS, Ribaudo HJ, Daar ES, Gulick RM, Haubrich RH, Robbins GK, de Bakker PI, Haas DW, McLaren PJ.

Pharmacogenet Genomics. 2015 Feb;25(2):51-9. doi: 10.1097/FPC.0000000000000106.

10.

Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.

Venuto CS, Mollan K, Ma Q, Daar ES, Sax PE, Fischl M, Collier AC, Smith KY, Tierney C, Morse GD.

J Antimicrob Chemother. 2014 Dec;69(12):3300-10. doi: 10.1093/jac/dku303. Epub 2014 Aug 25.

PMID:
25159623
11.

Antiretroviral therapy: treatment-experienced individuals.

Calvo KR, Daar ES.

Infect Dis Clin North Am. 2014 Sep;28(3):439-56. doi: 10.1016/j.idc.2014.06.005. Epub 2014 Jul 8. Review.

PMID:
25151565
12.

Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine.

Wyatt CM, Kitch D, Gupta SK, Tierney C, Daar ES, Sax PE, Ha B, Melbourne K, McComsey GA; AIDS Clinical Trials Group Study A5224s Team.

J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):36-44. doi: 10.1097/QAI.0000000000000245.

PMID:
25117929
13.

Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.

Mollan KR, Smurzynski M, Eron JJ, Daar ES, Campbell TB, Sax PE, Gulick RM, Na L, O'Keefe L, Robertson KR, Tierney C.

Ann Intern Med. 2014 Jul 1;161(1):1-10. doi: 10.7326/M14-0293. Erratum in: Ann Intern Med. 2014 Aug 19;161(4):308.

14.

Impaired Nef function is associated with early control of HIV-1 viremia.

Kuang XT, Li X, Anmole G, Mwimanzi P, Shahid A, Le AQ, Chong L, Qian H, Miura T, Markle T, Baraki B, Connick E, Daar ES, Jessen H, Kelleher AD, Little S, Markowitz M, Pereyra F, Rosenberg ES, Walker BD, Ueno T, Brumme ZL, Brockman MA.

J Virol. 2014 Sep 1;88(17):10200-13. doi: 10.1128/JVI.01334-14. Epub 2014 Jun 25.

15.

Short communication: HIV-1 gag genetic variation in a single acutely infected participant defined by high-resolution deep sequencing.

Al-Mawsawi LQ, Wu NC, De La Cruz J, Shi VC, Wu TT, Daar ES, Lewis MJ, Yang OO, Sun R.

AIDS Res Hum Retroviruses. 2014 Aug;30(8):806-11. doi: 10.1089/AID.2014.0097. Epub 2014 Jul 23.

PMID:
24914638
16.

Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens.

Zheng Y, Hughes MD, Lockman S, Benson CA, Hosseinipour MC, Campbell TB, Gulick RM, Daar ES, Sax PE, Riddler SA, Haubrich R, Salata RA, Currier JS.

Clin Infect Dis. 2014 Sep 15;59(6):888-96. doi: 10.1093/cid/ciu367. Epub 2014 May 19.

PMID:
24842909
17.

Ineffectual targeting of HIV-1 Nef by cytotoxic T lymphocytes in acute infection results in no functional impairment or viremia reduction.

De La Cruz J, Vollbrecht T, Frohnen P, Ng HL, Daar ES, Yang OO, Lewis MJ.

J Virol. 2014 Jul;88(14):7881-92. doi: 10.1128/JVI.00482-14. Epub 2014 Apr 30.

18.

Cytomegalovirus replication in semen is associated with higher levels of proviral HIV DNA and CD4+ T cell activation during antiretroviral treatment.

Gianella S, Massanella M, Richman DD, Little SJ, Spina CA, Vargas MV, Lada SM, Daar ES, Dube MP, Haubrich RH, Morris SR, Smith DM; California Collaborative Treatment Group 592 Team.

J Virol. 2014 Jul;88(14):7818-27. doi: 10.1128/JVI.00831-14. Epub 2014 Apr 30.

19.

Predictors of CNS injury as measured by proton magnetic resonance spectroscopy in the setting of chronic HIV infection and CART.

Harezlak J, Cohen R, Gongvatana A, Taylor M, Buchthal S, Schifitto G, Zhong J, Daar ES, Alger JR, Brown M, Singer EJ, Campbell TB, McMahon D, So YT, Yiannoutsos CT, Navia BA; HIV Neuroimaging Consortium.

J Neurovirol. 2014 Jun;20(3):294-303. doi: 10.1007/s13365-014-0246-6. Epub 2014 Apr 3.

20.

Impact of randomized antiretroviral therapy initiation on glucose metabolism.

Erlandson KM, Kitch D, Tierney C, Sax PE, Daar ES, Melbourne KM, Ha B, McComsey GA.

AIDS. 2014 Jun 19;28(10):1451-61. doi: 10.1097/QAD.0000000000000266.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk